These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36060608)

  • 41. Self-injected contraceptives: does the investment reflect women's preferences?
    Wood SN; Magalona S; Zimmerman LA; OlaOlorun F; Omoluabi E; Akilimali P; Guiella G; Gichangi P; Anglewicz P
    BMJ Glob Health; 2022 Jul; 7(7):. PubMed ID: 35835480
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Community-based distribution of injectable contraceptives in an African setting: community trial in Madagascar].
    Brunie A; Hoke TH; Razafindravony B
    Sante; 2011; 21(1):21-6. PubMed ID: 21550921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maintaining technical quality of care in the introduction of Cyclofem in a national family planning program: findings from Indonesia.
    Lubis F; Fajans P; Simmons R
    Contraception; 1994 May; 49(5):527-41. PubMed ID: 8045136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Perceptions of home and self-injection of Sayana® Press in Ethiopia: a qualitative study.
    Keith B; Wood S; Chapman C; Alemu E
    Contraception; 2014 May; 89(5):379-84. PubMed ID: 24529492
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
    Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
    Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.
    Williams RL; Hensel DJ; Fortenberry JD
    Contraception; 2013 Sep; 88(3):401-7. PubMed ID: 23294549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Women's experiences after Planned Parenthood's exclusion from a family planning program in Texas.
    Woo CJ; Alamgir H; Potter JE
    Contraception; 2016 Apr; 93(4):298-302. PubMed ID: 26680757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
    Potter LS; Dalberth BT; Cañamar R; Betz M
    Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Self-care provision of contraception: Evidence and insights from contraceptive injectable self-administration.
    Brady M; Drake JK; Namagembe A; Cover J
    Best Pract Res Clin Obstet Gynaecol; 2020 Jul; 66():95-106. PubMed ID: 32199705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
    Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
    Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Task-shifting the provision of DMPA-SC in the DR Congo: Perspectives from two different groups of providers.
    Hernandez JH; Akilimali P; Glover A; Emel R; Mwembo A; Bertrand J
    Contraception; 2018 Nov; 98(5):449-453. PubMed ID: 30031000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal.
    Burke HM; Mueller MP; Packer C; Perry B; Bufumbo L; Mbengue D; Daff BM; Mbonye A
    Contraception; 2014 May; 89(5):368-73. PubMed ID: 24576792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prospective cohort study to assess the acceptability of Sayana Press among 18-49-year-old women in Nepal.
    Sherpa LY; Tinkari BS; Gentle P; Sah RK; Shrestha A; Sahani SK; Aryal K; Ghimire J; Karki DK
    Contraception; 2021 Dec; 104(6):623-627. PubMed ID: 34280441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
    Cameron ST; Glasier A; Johnstone A
    Contraception; 2012 May; 85(5):458-64. PubMed ID: 22079602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Depot medroxyprogesterone. Management of side-effects commonly associated with its contraceptive use.
    Archer B; Irwin D; Jensen K; Johnson ME; Rorie J
    J Nurse Midwifery; 1997; 42(2):104-11. PubMed ID: 9107118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Introduction of cyclofem once-a-month injectable contraceptive in Mexico.
    Garza-Flores J; Moraks del Olmo A; Fuziwara JL; Figueroa JG; Alonso A; Monroy J; Perez M; Urbina-Fuentes M; Guevara SJ; Cedeno E; Barrios R; Ferman JJ; Medina LM; Velazquez E; Perez-Palacios G
    Contraception; 1998 Jul; 58(1):7-12. PubMed ID: 9743890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contraceptive introduction and the management of choice: the role of Cyclofem in Indonesia.
    Simmons R; Fajans P; Lubis F
    Contraception; 1994 May; 49(5):509-25. PubMed ID: 8045135
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Home-based administration of Sayana® Press: review and assessment of needs in low-resource settings.
    Keith B; Wood S; Tifft S; Hutchings J
    Contraception; 2014 May; 89(5):344-51. PubMed ID: 24813924
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
    Dragoman MV; Gaffield ME
    Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.